Rigel Pharmaceuticals reports Q3 EPS $1.46, consensus 94c

Reports Q3 revenue $69.5M, consensus $61.88M. “Our strong Q3 performance demonstrates our strategic focus on commercial execution, pipeline development, and financial discipline. We are raising our FY25 guidance due to our outstanding commercial performance year-to-date,” said Raul Rodriguez, Rigel’s president and CEO. “Our development pipeline continues to advance, including our ongoing Phase 1b study evaluating R289 for the treatment of patients with lower-risk MDS. With enrollment complete in the dose escalation phase of the study, we look forward to presenting updated data in an oral presentation at ASH in December. We’re also excited to have reached the next milestone of this program with the initiation of the dose expansion phase of the study.”